|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
26 October 2015 |
|
Main ID: |
NCT02159001 |
|
Date of registration:
|
04/06/2014 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Electroconvulsive Therapy in Clozapine-resistant Schizophrenia
|
|
Scientific title:
|
Efficacy and Cognitive Effects of Electroconvulsive Therapy in Clozapine-Resistant Schizophrenia |
|
Date of first enrolment:
|
June 2014 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT02159001 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Finland
| | | | | | | |
|
Contacts
|
|
Name:
|
Soile Hyvärinen, MD |
|
Address:
|
|
|
Telephone:
|
+358 295 242 219 |
|
Email:
|
soile.hyvarinen@niuva.fi |
|
Affiliation:
|
|
|
|
Name:
|
Eila Tiihonen, MD, PhD |
|
Address:
|
|
|
Telephone:
|
+358 295 242 204 |
|
Email:
|
eila.tiihonen@niuva.fi |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- diagnosis of schizophrenia or schizoaffective disorder
- treatment-resistant to clozapine
- age 18 - 64 years
- capacity and willingness to give informed consent
Exclusion Criteria:
- serious somatic illness
- progressive neurological illness, recent brain damage or sequela of serious brain
damage
- ECT less than 3 months prior to this trial
Age minimum:
18 Years
Age maximum:
64 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Schizophrenia
|
|
Schizoaffective Disorder
|
|
Intervention(s)
|
|
Device: electroconvulsive therapy
|
|
Primary Outcome(s)
|
|
Positive and Negative Symptom Scale
[Time Frame: 2 days]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|